DNC News


Inositol hexaphosphate (IP-6) and Breast Cancer


Subject:  Published data are become more convincing that IP-6 may be useful in the treatment of breast cancer.


Inositol hexaphosphate (IP-6) has been around for a number of years as a nutritional supplement.  It is sold as a way to promote immune function especially in the treatment of cancer.  I have had a standard line I've used when asked what I thought about it; "I would definitely take it if I was a rat."

IP-6 is a combination of Inositol and phytic acid, a chemical commonly found in wheat bran.  The early research on IP-6  involved a great number of rat studies.  Rats were injected with human cancer cell lines and adequate doses of IP-6 allowed them to survive.  I always had a lingering question whether this information could be extrapolated to humans.  Rats like to eat whole grains.  Perhaps their immune systems were more dependent on phytic acid than human immune systems. Would IP-6 play as big a role in humans as in rats? 

I did not know the answer but hesitated to put IP-6 on the top of my lists for cancer patients.  It is time to change that idea.  Whether or not IP-6 will act as a stimulant to the human immune system isn't as important as I first thought.  IP-6 on its own, irregardless of immune system involvement, is starting to look like a valuable player, especially in breast cancer.

First it now appears that IP-6 will slow the growth rate of various cancer cells including both estrogen positive and negative breast cancer cells and colon cancer cells by about 20%. [1]

Second, IP-6 enhances the effects of Adriamycin and tamoxifen in breast cancer.  A recent study looked at the effect of IP-6 on three breast cancer cell lines, one estrogen receptor positive, one estrogen receptor negative and one Adriamycin resistant.  All three cell lines were sensitive to the growth inhibitory effects of IP-6.  The "data not only confirm the IP-6 alone inhibits growth of breast cancer cells; but it also acts synergistically with Adriamycin or tamoxifen, being particularly effective against ER alpha-negative cells and Adriamycin-resistant cell lines." [2]

Third, IP-6 may inhibit cancer cell metastasis.  Two studies came out in Fall, 2003 examining the effect IP-6 has on metastasis.  Both were very favorable.  In the first, "cell invasion also was decreased (by 72% after IP6 treatment, p = 0.001) in a dose-dependent fashion." in a breast cancer cell model.  [3] The second study focused on explaining the mechanism by which IP-6 inhibits metastasis, concluding ": The results of this study indicate that IP6-induced inhibition of cancer cell adhesion, migration and invasion may be mediated through the modulation of integrin dimerization, cell surface expression and integrin-associated signaling pathway."   [4]   (If that means anything to you?)

All of these studies continue to be either in vitro (test tube) or in vivo (in living subjects) but at this point not humans yet they are starting to add up, especially when talking about breast cancer.  Inhibition of growth, synergistic effects with chemotherapy, effect on drug resistant strains and slowing metastasis are all, each on their own, good reasons to take this supplement seriously. 


  1. Anticancer Res. 2001 Jul-Aug;21(4A):2393-403  G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). El-Sherbiny YM, Cox MC, Ismail ZA, Shamsuddin AM, Vucenik I.
 2.  Breast Cancer Res Treat. 2003 Jun;79(3):301-12.  Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. Tantivejkul K, Vucenik I, Eiseman J, Shamsuddin AM.
  3. Anticancer Res. 2003 Sep-Oct;23(5A):3671-9 Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: I. In vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells. Tantivejkul K, Vucenik I, Shamsuddin AM.
  4. Anticancer Res. 2003 Sep-Oct;23(5A):3681-9 Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II. Effects on integrins and focal adhesions.Tantivejkul K, Vucenik I, Shamsuddin AM.


................................................................
Hey! You're getting these newsletters either because you've signed up to be on the list or because we took the liberty of putting you on.  If you want your name removed simply leave a message at the office (303-337-4884) or go to the website: denvernaturopathic.com and unsubscribe, or reply with the message "REMOVE" in the subject line.  If on the other hand you want to be added to the mailing list follow the prior instructions but subscribe. We are finally trying to keep up with our website and are posting most of these newsletters in our 'archive' section.  Frequently we also post abstracts of references quoted for the intellectually curious.

 


Ask the Doctor:
What's the difference between naturopathy and homeopathy?

[click here for the answer]

Submit your question here.


Newsletter:
Enter your email to recieve the latest Health and Wellness newsletters from the clinic.